On Tuesday, October 15, 2024, the Forum for Collaborative Research convened its 11^th TAVI Forum meeting at the Hotel Indigo Los Angeles Downtown in Los Angeles, California, USA. The goal of the TAVI Forum is to advance the regulatory sciences for the treatment of TAVI and its associated morbidities by providing an independent and neutral venue for ongoing multi-stakeholder dialogue.

Materials

Agenda

Participant List

Presentations

Introductory Remarks
Welcome and Introductions
Shilpa Mitra, Forum for Collaborative Research
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska University Hospital
Camille Kotton, Massachusetts General Hospital

Session I: New Topics in Transplant and Immunocompromised Populations
Torque Teno Virus-based Immunologic Monitoring
Gregor Bond, Medical University of Vienna*
Discussion
All

A New Approach for Preventing Acute Respiratory Viral Infections in Immunocompromised Individuals
Warner Greene, Gladstone Institutes UC San Francisco
Antivirals for the Prevention and Treatment of Respiratory Viruses in the Immunocompromised
Michael G. Ison, NIAID
Discussion
All

The Next Outbreak Looms on the Horizon: Measles and Potential Impacts on Transplant Recipients
Camille Kotton, Massachusetts General Hospital
Discussion
All

Challenges and Opportunities in the Clinical Development of Antivirals
Anna Wald, University of Washington
Discussion
All

Session II: Working Group Updates
The Road to Development of Preventive and Therapeutic Treatments for Human Herpesvirus 6B (HHV-6B): An Update
Joshua Hill, Fred Hutchinson Cancer Center*
Interactive Survey & Discussion
All

Can BKPyV PCR be a Surrogate Marker in Kidney Transplant Recipients?: A Systematic Review and Meta-analysis
Yoichiro Natori, University of Miami
Discussion
All

The Adenovirus Challenge: An Update
Thomas Lion, Labdia Labordiagnostik
Discussion
All

CMV Cell-Immune Monitoring for Predicting CMV-Outcomes in SOT Recipients: A Systematic Review
Cesar G. Berto, University of Alabama at Birmingham
Toward Functional CMV Immune-Monitoring for Predicting CMV-Mediated Events in HCT Recipients
Alexandre Malek, Ochsner LSU Health
Discussion
All

Concluding Remarks
Next Steps
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska University Hospital
Camille Kotton, Massachusetts General Hospital

*Remote participation